Rayscape
Uses artificial intelligence algorithms to help radiologists fare better at their everyday tasks.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | €500k Valuation: €5.0m 118.4x EV/Revenue | Seed | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 193 % | (76 %) | 84 % | (38 %) | 65 % | (41 %) | (30 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 46 % | (80 %) | 9 % | (33 %) | 14 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 45 % | (85 %) | 2 % | (40 %) | 9 % | 8 % | 38 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Rayscape, formerly known as XVision, is a Romanian-based HealthTech company established in 2018 by a team including Andrei Tenescu, Cristian Avramescu, Bogdan Bercean, and Stefan Iarca. The firm operates in the diagnostic software market, developing artificial intelligence-based solutions to augment the capabilities of radiologists. Its target clients include hospitals, private healthcare networks, and imaging centers, with partners such as MedLife and Regina Maria Healthcare Network in Romania.
The company's core offering is an AI-powered digital assistant designed to analyze medical images, specifically chest X-rays and lung CT scans. The business model likely operates on a subscription or pay-per-use basis, providing its software as a service (SaaS) that integrates with existing hospital infrastructure like PACS or cloud systems. Rayscape has secured funding from investors including Fortech Investments, bValue Fund, and Gapminder, and announced a €500,000 investment in March 2024 to facilitate its expansion into the U.S. market.
Rayscape’s product suite is engineered to enhance diagnostic accuracy and workflow efficiency. The Rayscape CXR tool can identify over 148 pathologies on chest X-rays, calculate the cardiothoracic index, and prioritize cases based on urgency. Its Lung CT product focuses on the detection, measurement, and tracking of pulmonary nodules with diameters between 3-30mm. The software provides quantitative analysis, such as nodule volume and a malignancy score, and can automatically compare changes across follow-up scans, which is crucial for oncology patients. During the COVID-19 pandemic, the platform was adapted to include a triage score based on the severity of detected lung pathologies, helping doctors manage increased caseloads. The system is designed for seamless integration and can generate customizable, structured reports with both visual and textual outputs to fit a radiologist's workflow.
Keywords: medical imaging, radiology AI, digital assistant, diagnostic software, chest X-ray analysis, lung CT scans, pulmonary nodule detection, HealthTech, clinical decision support, medical diagnostics